Head-to-head analysis comparing Tirzepatide and Semaglutide. Understand differences in weight loss percentage, nausea rates, and metabolic glycemic control.
In head-to-head SURPASS-2 trials, Tirzepatide delivered statistically significant superior weight reduction (approx. 20.9% vs 14.9%) and greater HbA1c reductions with comparable or slightly milder nausea profiles.
| Evaluation Feature | Tirzepatide | Semaglutide | Analytical Winner / Takeaway |
|---|---|---|---|
| Receptor Profile | Dual GIP / GLP-1 Agonist | Selective GLP-1 Agonist | Tirzepatide has dual pathway activation |
| Head-to-Head Weight Loss | ~20.9% average body weight loss | ~14.9% average body weight loss | Tirzepatide achieves greater total reduction |
| GI Side Effect Severity | Moderate; GIP helps buffer intense nausea | Moderate to high nausea during rapid titration | Tirzepatide often tolerated slightly better at equivalent efficacy |
Semaglutide is a selective mono-agonist for the GLP-1 receptor. Tirzepatide combines GLP-1 receptor agonism with GIP receptor agonism, which buffers metabolic lipid storage and allows higher GLP-1 tolerability without excessive nausea.
Both are once-weekly subcutaneous injections. Semaglutide has a half-life of ~7 days, while Tirzepatide is ~5 days.
Semaglutide maxes out at 2.4mg weekly; Tirzepatide scales up to 15mg weekly.
These two should not be taken simultaneously as they compete for identical GLP-1 binding domains.
Tirzepatide is generally superior in total fat loss and glycemic potency. Semaglutide has slightly longer commercial cardiovascular outcome trial (CVOT) data (SELECT trial).